Identification of novel mutations in endometrial cancer patients by whole-exome sequencing

Chang,Ya-Sian; Huang,Hsien-Da; Yeh,Kun-Tu; Chang,Jan-Gowth

doi:10.3892/ijo.2017.3919

Identification of novel mutations in endometrial cancer patients by whole-exome sequencing

Authors:
- Ya-Sian Chang
- Hsien-Da Huang
- Kun-Tu Yeh
- Jan-Gowth Chang
View Affiliations

Affiliations: Epigenome Research Center, China Medical University Hospital, Taichung 404, Taiwan, R.O.C., Department of Biological Science and Technology, National Chiao Tung University, Hsinchu 300, Taiwan, R.O.C., Department of Pathology, Changhua Christian Hospital, Changhua 500, Taiwan, R.O.C.
Published online on: March 20, 2017 https://doi.org/10.3892/ijo.2017.3919
Pages: 1778-1784

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to identify genomic alterations in Taiwanese endometrial cancer patients. This information is vitally important in Taiwan, where endometrial cancer is the second most common gynecological cancer. We performed whole-exome sequencing on DNA from 14 tumor tissue samples from Taiwanese endometrial cancer patients. We used the Genome Analysis Tool kit software package for data analysis, and the dbSNP, Catalogue of Somatic Mutations in Cancer (COSMIC) and The Cancer Genome Atlas (TCGA) databases for comparisons. Variants were validated via Sanger sequencing. We identified 143 non-synonymous mutations in 756 canonical cancer-related genes and 1,271 non-synonymous mutations in non-canonical cancer-related genes in 14 endometrial samples. PTEN, KRAS and PIK3R1 were the most frequently mutated canonical cancer-related genes. Our results revealed nine potential driver genes (MAPT, IL24, MCM6, TSC1, BIRC2, CIITA, DST, CASP8 and NOTCH2) and 21 potential passenger genes (ARMCX4, IGSF10, VPS13C, DCT, DNAH14, TLN1, ZNF605, ZSCAN29, MOCOS, CMYA5, PCDH17, UGT1A8, CYFIP2, MACF1, NUDT5, JAKMIP1, PCDHGB4, FAM178A, SNX6, IMP4 and PCMTD1). The detected molecular aberrations led to putative activation of the mTOR, Wnt, MAPK, VEGF and ErbB pathways, as well as aberrant DNA repair, cell cycle control and apoptosis pathways. We characterized the mutational landscape and genetic alterations in multiple cellular pathways of endometrial cancer in the Taiwanese population.

View Figures

View References

1	Sénéchal C, Cottereau E, de Pauw A, Elan C, Dagousset I, Fourchotte V, Gauthier-Villars M, Lae M, Stoppa-Lyonnet D and Buecher B: Environmental and genetic risk factors for endometrial carcinoma. Bull Cancer. 102:256–269. 2015.In French. View Article : Google Scholar
2	Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U and Scott RJ: Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. Cancer Epidemiol. 34:328–337. 2010. View Article : Google Scholar : PubMed/NCBI
3	Xu J, Lin X, Zhu H, Zhang Z and Yang B: Genetic variation of the CYP17 and susceptibility to endometrial cancer: A meta-analysis. Mol Biol Rep. 40:5085–5091. 2013. View Article : Google Scholar : PubMed/NCBI
4	Collaborative Group on Epidemiological Studies on Endometrial Cancer: Endometrial cancer and oral contraceptives: An individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 16:1061–1070. 2015. View Article : Google Scholar : PubMed/NCBI
5	Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck AR, Park Y and Brinton LA: Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer. 132:417–426. 2013. View Article : Google Scholar
6	Brinton LA, Westhoff CL, Scoccia B, Lamb EJ, Trabert B, Niwa S and Moghissi KS: Fertility drugs and endometrial cancer risk: Results from an extended follow-up of a large infertility cohort. Hum Reprod. 28:2813–2821. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ong M, Carreira S, Goodall J, Mateo J, Figueiredo I, Rodrigues DN, Perkins G, Seed G, Yap TA, Attard G, et al: Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br J Cancer. 111:828–836. 2014. View Article : Google Scholar : PubMed/NCBI
8	André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, et al: Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 15:267–274. 2014. View Article : Google Scholar : PubMed/NCBI
9	Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
10	Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, et al Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar
11	Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al Cancer Genome Atlas Research Network: Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI
13	Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, Leamon J, Andersen M and Corless CL: Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn. 15:171–176. 2013. View Article : Google Scholar : PubMed/NCBI
14	Grasso C, Butler T, Rhodes K, Quist M, Neff TL, Moore S, Tomlins SA, Reinig E, Beadling C, Andersen M, et al: Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. J Mol Diagn. 17:53–63. 2015. View Article : Google Scholar
15	Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, et al: Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 20:1479–1484. 2014. View Article : Google Scholar : PubMed/NCBI
16	Samorodnitsky E, Datta J, Jewell BM, Hagopian R, Miya J, Wing MR, Damodaran S, Lippus JM, Reeser JW, Bhatt D, et al: Comparison of custom capture for targeted next-generation DNA sequencing. J Mol Diagn. 17:64–75. 2015. View Article : Google Scholar :
17	Drmanac R, Peters BA, Church GM, Reid CA and Xu X: Accurate whole genome sequencing as the ultimate genetic test. Clin Chem. 61:305–306. 2015. View Article : Google Scholar
18	Park JY, Clark P, Londin E, Sponziello M, Kricka LJ and Fortina P: Clinical exome performance for reporting secondary genetic findings. Clin Chem. 61:213–220. 2015. View Article : Google Scholar :
19	Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, et al: Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 22:2120–2129. 2012. View Article : Google Scholar : PubMed/NCBI
20	Langmead B, Trapnell C, Pop M and Salzberg SL: Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10:R252009. View Article : Google Scholar : PubMed/NCBI
21	McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al: The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
22	Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM and Sirotkin K: dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 29:308–311. 2001. View Article : Google Scholar :
23	Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM and Maglott DR: ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42(D1): D980–D985. 2014. View Article : Google Scholar :
24	Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, et al: COSMIC: Exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43(D1): D805–D811. 2015. View Article : Google Scholar :
25	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R and Larsson E: Integrative analysis of complex cancer genomics and clinical profiles using the cBio-Portal. Sci Signal. 6:pl12013. View Article : Google Scholar
26	Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS and Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods. 7:248–249. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kumar P, Henikoff S and Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 4:1073–1081. 2009. View Article : Google Scholar : PubMed/NCBI
28	Hua X, Xu H, Yang Y, Zhu J, Liu P and Lu Y: DrGaP: A powerful tool for identifying driver genes and pathways in cancer sequencing studies. Am J Hum Genet. 93:439–451. 2013. View Article : Google Scholar : PubMed/NCBI
29	Chang YS, Huang HD, Yeh KT and Chang JG: Genetic alterations in endometrial cancer by targeted next-generation sequencing. Exp Mol Pathol. 100:8–12. 2016. View Article : Google Scholar
30	Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, et al: Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 17:385–399. 2015. View Article : Google Scholar : PubMed/NCBI
31	Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, et al: Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res. 22:2445–2452. 2016. View Article : Google Scholar : PubMed/NCBI
32	Choschzick M, Tabibzada AM, Gieseking F, Woelber L, Jaenicke F, Sauter G and Simon R: BIRC2 amplification in squamous cell carcinomas of the uterine cervix. Virchows Arch. 461:123–128. 2012. View Article : Google Scholar : PubMed/NCBI
33	Ma XY, Ma CX and Wang JH: Endometrial carcinogenesis and molecular signaling pathways. Am J Mol Biol. 4:134–149. 2014. View Article : Google Scholar
34	Nam JY, Kim NK, Kim SC, Joung JG, Xi R, Lee S, Park PJ and Park WY: Evaluation of somatic copy number estimation tools for whole-exome sequencing data. Brief Bioinform. 17:185–192. 2016. View Article : Google Scholar